Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
Table 2
Mean change from baseline in circulating vitamin D metabolites, plasma PO4, and FGF-23 by study group.
Characteristics
Vitamin D group
Placebo group
Treatment effect
value3
Baseline
Follow-up (36 months)
Mean change from baseline1
Baseline
Follow-up (36 months)
Mean change from baseline1
Adjusted between-group differences2
25OHD (nmol/L)
36.9 (32.8–40.9)
100.3 (87.6–112.9)
65.8 (54.5 to 77.1)
36.7 (32.8–40.6)
46.9 (41.4–45.3)
9.6 (3.8 to 15.4)
50.5 (37.9 to 63.2)
<0.001
1,25(OH)2D pmol/L)
82.0 (75.1–88.8)
96.5 (85.8–105.2)
12.2 (3.2 to 21.3)
90.4 (82.3–98.5)
82.7 (74.7–90.9)
−8.1 (−15.8 to −0.6)
18.3 (7.3 to 29.3)
<0.001
Phosphate (mmol/L)
0.88 (0.84–0.93)
1.09 (0.92–1.27)
0.21 (0.05 to 0.37)
0.98 (0.93–1.03)
0.96 (0.91–1.01)
0.00 (−0.07 to 0.06)
0.18 (−0.00 to 0.35)
0.051
FGF-23 (RU/mL)
146 (106–187)
977 (135–1819)
811 (−2 to 1623)
179 (88–268)
304 (154–454)
132 (14 to 250)
685 (−213 to 15,850)
0.134
1Change from baseline data is shown as mean and 95% confidence interval of the mean; 2between group differences at study termination, with adjustments for baseline values, and initial age and phosphate level; 3probability of between group differences at study termination, with adjustments for baseline values and initial age, phosphate, and aldosterone levels (ANCOVA). versus baseline; versus baseline; versus baseline (Wilcoxon test). 1,25(OH)2D: 1,25-dihydroxyvitamin D; 25OHD: 25-hydroxyvitamin D; FGF: fibroblast growth factor.
